Did Rubedo’s experimental drug really make skin two years younger? Phase 1b data reveal a surprising signal
Rubedo's RLS-1496 reduces measured skin epigenetic age by 2.1 years in early research, but clinical benefits remain to be proven.
Pharma & Biotech
Medical Devices & Diagnostics
Vista AI raises $29.5m to expand automated MRI scanning beyond cardiology
Vista AI, a U.S.-based medical imaging software company specializing in AI-powered MRI automation, has raised $29.5 million in Series B financing to accelerate its product roadmap and scale adoption across U.S. hospitals and imaging centers. The funding round, announced on January 14, 2026, includes strategic investments from leading health systems such as Cedars-Sinai Health System,